Vaccination for the control of childhood bacterial pneumonia - Haemophilus influenzae type b and pneumococcal vaccines
<p class="MsoNoSpacing"><span style="font-size: 7.5pt; font-family: Verdana, sans-serif; background-position: initial initial; background-repeat: initial initial;">Pneumonia in childhood is endemic in large parts of the world and in particular, in developing countries...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2013-01-01
|
Series: | Pneumonia |
Subjects: | |
Online Access: | https://pneumonia.org.au/index.php/pneumonia/article/view/229 |
id |
doaj-aa8d1daf12834d7faded0e891b15afdb |
---|---|
record_format |
Article |
spelling |
doaj-aa8d1daf12834d7faded0e891b15afdb2020-11-25T01:13:32ZengBMCPneumonia2200-61332013-01-012021510.15172/pneu.2013.2/229192Vaccination for the control of childhood bacterial pneumonia - Haemophilus influenzae type b and pneumococcal vaccinesDiana C Otczyk0Allan W Cripps1Menzies Health Instutute, Griffith UniversityGriffith University<p class="MsoNoSpacing"><span style="font-size: 7.5pt; font-family: Verdana, sans-serif; background-position: initial initial; background-repeat: initial initial;">Pneumonia in childhood is endemic in large parts of the world and in particular, in developing countries, as well as in many indigenous communities within developed nations. Haemophilus influenzae type b and Streptococcus pneumoniae conjugate vaccines are currently available against the leading bacterial causes of pneumonia. The use of the vaccines in both industrialised and developing countries have shown a dramatic reduction in the burden of pneumonia and invasive disease in children. However, the greatest threat facing pneumococcal conjugate vaccine effectiveness is serotype replacement. The current vaccines provide serotype-specific, antibody–mediated protection against only a few of the 90+ capsule serotypes. Therefore, there has been a focus in recent years to rapidly advance technologies that will result in broader disease coverage and more affordable vaccines that can be used in developing countries. The next generation of pneumococcal vaccines have advanced to clinical trials.</span></p>https://pneumonia.org.au/index.php/pneumonia/article/view/229pneumonia, bacteria, Haemophilus influenzae type b, Streptococcus pneumoniae, vaccine, WHO. |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Diana C Otczyk Allan W Cripps |
spellingShingle |
Diana C Otczyk Allan W Cripps Vaccination for the control of childhood bacterial pneumonia - Haemophilus influenzae type b and pneumococcal vaccines Pneumonia pneumonia, bacteria, Haemophilus influenzae type b, Streptococcus pneumoniae, vaccine, WHO. |
author_facet |
Diana C Otczyk Allan W Cripps |
author_sort |
Diana C Otczyk |
title |
Vaccination for the control of childhood bacterial pneumonia - Haemophilus influenzae type b and pneumococcal vaccines |
title_short |
Vaccination for the control of childhood bacterial pneumonia - Haemophilus influenzae type b and pneumococcal vaccines |
title_full |
Vaccination for the control of childhood bacterial pneumonia - Haemophilus influenzae type b and pneumococcal vaccines |
title_fullStr |
Vaccination for the control of childhood bacterial pneumonia - Haemophilus influenzae type b and pneumococcal vaccines |
title_full_unstemmed |
Vaccination for the control of childhood bacterial pneumonia - Haemophilus influenzae type b and pneumococcal vaccines |
title_sort |
vaccination for the control of childhood bacterial pneumonia - haemophilus influenzae type b and pneumococcal vaccines |
publisher |
BMC |
series |
Pneumonia |
issn |
2200-6133 |
publishDate |
2013-01-01 |
description |
<p class="MsoNoSpacing"><span style="font-size: 7.5pt; font-family: Verdana, sans-serif; background-position: initial initial; background-repeat: initial initial;">Pneumonia in childhood is endemic in large parts of the world and in particular, in developing countries, as well as in many indigenous communities within developed nations. Haemophilus influenzae type b and Streptococcus pneumoniae conjugate vaccines are currently available against the leading bacterial causes of pneumonia. The use of the vaccines in both industrialised and developing countries have shown a dramatic reduction in the burden of pneumonia and invasive disease in children. However, the greatest threat facing pneumococcal conjugate vaccine effectiveness is serotype replacement. The current vaccines provide serotype-specific, antibody–mediated protection against only a few of the 90+ capsule serotypes. Therefore, there has been a focus in recent years to rapidly advance technologies that will result in broader disease coverage and more affordable vaccines that can be used in developing countries. The next generation of pneumococcal vaccines have advanced to clinical trials.</span></p> |
topic |
pneumonia, bacteria, Haemophilus influenzae type b, Streptococcus pneumoniae, vaccine, WHO. |
url |
https://pneumonia.org.au/index.php/pneumonia/article/view/229 |
work_keys_str_mv |
AT dianacotczyk vaccinationforthecontrolofchildhoodbacterialpneumoniahaemophilusinfluenzaetypebandpneumococcalvaccines AT allanwcripps vaccinationforthecontrolofchildhoodbacterialpneumoniahaemophilusinfluenzaetypebandpneumococcalvaccines |
_version_ |
1725161696159334400 |